* Alteon Inc., of Ramsey, N.J., completed enrollment of 660 patientsfor its Phase III trial of pimagedine to treat type I diabetics withkidney disease. Data from the study, called ACTION-I (A ClinicalTrial In Overt Nephropathy), will be unblinded following itscompletion in the third quarter of 1998. The company's ACTION-IItrial of pimagedine is an ongoing Phase III study for type II diabetes.
* La Jolla Pharmaceutical Co., of San Diego, said it raised anadditional $700,000 associated with its July 2, 1996 public offeringwhen underwriters exercised overallotment options for 140,000shares. The company raised a total of $10.7 million in the equityfinancing. Underwriters were Robertson, Stephens & Co. LLC,Pacific Growth Equities Inc. and Van Kasper & Co., all of SanFrancisco, and Vector Securities International Inc., of Deerfield, Ill.
(c) 1997 American Health Consultants. All rights reserved.